BSE 500 52-week highs: 20 stocks hit peaks in 2026

A broad set of BSE 500 stocks recorded fresh 52-week highs on 7 July 2026, with 20 names touching new yearly peaks during the session. The list was led by Titan Company at ₹4,655, followed by IndusInd Bank at ₹1,034.60 and GMR Airports at ₹115.30.

The day’s moves reflected a mix of stock-specific triggers and deal-related developments. Titan’s run-up came after back-to-back bullish brokerage notes from CLSA, Citi and Nomura, which followed the company’s strong Q1 FY27 update. Separately, JB Chemicals & Pharmaceuticals and Torrent Pharmaceuticals featured among the names at fresh highs after a key legal step in their merger process was cleared.

Session snapshot: new highs across sectors

The 52-week-high list included companies from consumer discretionary, banking, airports, pharmaceuticals, and energy. While the broader market context is not detailed here, the trading action points to a session where investors were willing to pay up for momentum names, especially those supported by clear corporate events.

Titan’s position at the top of the list stood out because it was linked directly to analyst commentary and a recent business update. In contrast, the pharma names drew attention because the catalyst was regulatory and structural, tied to a merger that has been working through statutory approvals.

Titan leads after brokerage notes post Q1 FY27 update

Titan Company touched ₹4,655, which was also the stock’s day’s high, while the CMP stood at ₹4,584.45. The move followed back-to-back bullish notes from CLSA, Citi and Nomura, issued after Titan’s Q1 FY27 update.

This is a typical setup seen in large-cap consumer names, where a strong operating update prompts revisions to expectations and triggers incremental buying. The article notes the brokerage updates as the key driver for Titan’s fresh peak on the day.

Why JB Chemicals and Torrent Pharma hit 52-week highs

JB Chemicals & Pharmaceuticals and Torrent Pharmaceuticals both appeared on the 52-week-high list after the National Company Law Tribunal (NCLT) approved their merger scheme earlier in the day.

In regulatory filings, JB Chemicals said the merger with Torrent Pharmaceuticals Limited has been approved by the NCLT through an order dated 6 July 2026, in accordance with the Companies Act, 2013. Both companies also said the NCLT had sanctioned the scheme of amalgamation under Sections 230 to 232 of the Act.

The merger will become effective after the certified copy of the tribunal’s order is filed with the Registrar of Companies (RoC), following which the companies will announce the effective date. The approval also follows shareholders of both companies voting in favour of the scheme at NCLT-convened meetings held in April 2026.

Key data: BSE 500 stocks at 52-week highs (selected)

The session’s high list included the following names and price points that were reported.

Merger timeline: JB Chemicals and Torrent Pharma

The filings and tribunal process outline a multi-step sequence leading up to the latest approval.

Market impact: what changed for investors on 7 July

For Titan, the market impact was visible in the price action toward the top of the list, supported by the sequence of brokerage notes after the company’s Q1 FY27 update. The stock’s reported numbers show a day’s high and 52-week high at ₹4,655, versus a CMP of ₹4,584.45.

For JB Chemicals and Torrent Pharma, the immediate impact was the validation of a major corporate action clearing a key regulatory hurdle. The NCLT approval is not the final operational merger date, but it is a meaningful step because the scheme becomes effective only after the certified order is filed with the RoC and the companies announce the effective date.

The update also came alongside recent trading reference points: JB Chemicals closed at ₹2,390 on the NSE on Monday, up 1.07%, while Torrent Pharma settled 1.14% higher at ₹4,822.70.

Deal context: acquisition size and expected cost savings

The consolidation is described as one of the larger deals in India’s pharmaceutical sector. Torrent Pharmaceuticals has cited efforts to streamline operations to unlock ₹450 crore in cost savings following its ₹25,700 crore acquisition of JB Pharma. Separately, the expected synergies were also described as ₹400-450 crore over the next three years.

Torrent also stated that after acquiring a controlling stake in JB Pharma, its consolidated financial statements include JB Pharma, its subsidiaries, and related acquisition effects from 21 January 2026.

Stock performance context highlighted for JB and Torrent

Historical return data was also provided for JB Chemicals & Pharmaceuticals, showing gains of +1.31% (1 day), +11.43% (1 month), +28.91% (6 months), +48.28% (1 year), and +171.90% (5 years).

For Torrent Pharma, additional context included trading and market metrics: at 10:45 AM, Torrent Pharma shares were reported at ₹4,659 on the NSE, up 3.85%. The stock has gained 10% over a month, over 24% in six months, 21% from the beginning of the year, and 46% year-on-year, with a reported market capitalisation of ₹1.57 lakh crore.

What to watch next

The next formal step for the merger becoming effective is procedural but important: filing the certified copy of the NCLT order with the Registrar of Companies. After that filing, the companies are expected to announce the effective date.

For the broader 52-week-high list, the session highlighted how catalysts vary stock by stock, ranging from analyst reactions to quarterly updates to regulatory approvals for large corporate restructuring.